Aging and symposium on geroprotectors

Aging lies at the core of every age-related disease and affects every person on the planet. It represents an unbearable toll on the economies of the developed countries resulting in over two trillion dollars in direct medical costs, costs of caring and lost productivity in the US and EU alone. Yet, pharmaceutical companies fail to see the practical applications of aging research as many early experiments with drugs that held promise in slowing the aging processes resulted in commercial failures and write offs. Lack of business models, regulation and absence of a clear set of aging biomarkers make it difficult for large pharmaceutical companies to fully engage in aging research. Unlike other events that are geared towards academia or have a broad range of topics, this forum intends to focus on drug discovery and pharmaceuticals that may have a role in postponing the aging processes, preventing the age-related diseases and evaluating the effectiveness of various small molecules with geroprotective properties. I'd like to invite you to:

International Symposium on Geroprotectors: Practical Applications of Aging Research for Drug Discovery

Dates: September 23 – 24, 2014
Location: Basel, Switzerland

 

The event will showcase the research projects in aging research to the leaders of the pharmaceutical industry. The symposium will comprise into the three sessions relevant to the drug discovery companies. Each session will be chaired by the top expert in the field:

Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session II: Drugs with the potential geroprotective properties
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy?
Session IV: Trends in Aging Research and Drug DiscoveryThe forum is part of MipTek 2014, the largest drug discovery conference in Europe attracting over 3,000 delegates from the pharmaceutical industry.

The forum is organized by:Alex Zhavoronkov, PhD  (The Biogerontology Research Foundation, UK)
and Bhupinder Bullar, PhD (Novartis Pharma AG, Switzerland)

 

Links:

http://www.kurzweilai.net/international-symposium-on-geroprotectors-practical-applications-of-aging-research-for-drug-discovery
http://www.agingpharma.org/
http://www.biotechnologymeetings.com/

Professor Charles Cantor joins InSilico Medicine, Inc. in the War on Aging as the Chair of the SAB

The Former Head of the Human Genome Project Joins InSilico Medicine, Inc. in the War on Aging as the Chair of the SAB

Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer-reviewed articles, authored and co-authored more than 50 U.S. and international patents. He is also an author of the first genomics textbook, "Genomics: The Science and Technology of the Human Genome Project" and the three-volume textbook "Biophysical Chemistry". 

Charles Cantor, PhD, professor emeritus at Boston University and former principal scientist of the Human Genome Project joined the Science Advisory Board of InSilico Medicine, Inc.

"Aging is one of the most pressing problems facing the economies of the developed countries and there is an urgent need for new ways to increase productive longevity and screening the known drugs for their geroprotective properties and personalizing anti-cancer and aging-suppressive regiments using genetic and epigenetic analysis is one of the low hanging fruits in applied aging research. I am pleased to join the SAB of this international team dedicated to develop working solutions for both aging and age-related diseases", said Charles Cantor, PhD, chair of the Science Advisory Board of InSilico Medicine, Inc.

Dr. Cantor was the chairman of Genetics and Development at Columbia University College of Physicians & Surgeons, and Professor of Molecular Biology, University of California, Berkeley.

For more information please visit http://www.InSilicoMedicine.com .

Contact @ Insilico Medicine, Inc.:

InSilico Medicine, Inc.
Johns Hopkins University Eastern Campus
B301, 1101 East 33rd Street
Baltimore, MD 21218

Qinsong Zhu, PhD
Chief Operating Officer
+14107109674
zhu@insilicomedicine.com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/InSilico/Medicine/prweb11904553.htm